Medication affordability, health policy, and informed prescribing within the United States
Jerry Avorn, Professor of Medicine at Harvard Medical School, presented an analysis of the U.S. healthcare system's challenges regarding medication affordability, highlighting three core areas: policy, payment, and prescribing (3:30-18:40).
The Problem of "American Exceptionalism" (3:30-5:30):
U.S. drug prices are approximately double those in other wealthy nations for the same products.
This leads to significant non-adherence; roughly half of chronic medications are not taken as directed, with 20-25% of patients reporting inability to afford their prescriptions.
Medications are a primary driver of rising U.S. healthcare costs, which do not correlate with better health outcomes compared to other nations.
Policy Challenges (6:15-8:45):
Pricing Limitations: Laws restrict government negotiation of drug prices for Medicare, and federal programs are often mandated to cover expensive, sometimes overpriced, drugs.
Cost-Effectiveness Barriers: Use of quality-adjusted life-year (QALY) metrics is prohibited in many federal programs.
Patent Abuse: Current patent laws allow for "evergreening"—unreasonable extensions via secondary and tertiary patents that prevent timely generic market entry.
Payment & PBM Complications (8:45-10:05):
Manufacturers set prices without government negotiation, a unique U.S. model.
Pharmacy Benefit Managers (PBMs): These entities extract profits via secret rebates with manufacturers to determine formulary placement, making pricing opaque.
Coverage Reductions: Significant cutbacks in subsidies and Medicaid are projected to reduce access to medication coverage.
Prescribing & Education (10:08-11:50):
Medical education provides insufficient training on evidence-based, cost-effective prescribing.
Industry Influence: The U.S. and New Zealand are the only countries allowing direct-to-consumer advertising, with billions spent annually by industry to promote high-cost drugs over lower-cost alternatives.
Proposed Solutions (12:20-19:50):
Structural Reform: Enable government drug price negotiation, mirror the VA’s successful closed-formulary model, and prohibit secret PBM rebate deals.
Evidence-Based Tools: Increase the use of independent cost-effectiveness reviews (like those from ISER) and stop the abuse of secondary patents.
Clinical Education: Improve physician training on medications and leverage "academic detailing"—non-industry-sponsored educational outreach—to provide doctors with unbiased, evidence-based, and cost-effective information.
